Cytosorbents Corporation (NASDAQ:CTSO) jumped 17.50% after the FDA approved the company’s Investigational Device Exemption request for DrugSorb-ATR Antithrombotic Removal (ATR) device. With the approval, the company can now move forward with START-T clinical trials evaluating the device in the US for removal of intraoperative ticagrelor during cardiothoracic operation. The company will conduct the study under …
Continue reading “Cytosorbents Corporation (CTSO) Stock Breakout Alert: How to Trade Now?”